European payers report pricing concerns for asthma drug Relvar

  • July 25, 2014

Pulmonologists and payers in five European Union countries had mixed views of the first once-daily long-acting beta2-agonist and inhaled corticosteroid fixed dose combination for treating asthma, according to survey results.

Up to 50% of the surveyed pulmonologists from France, Germany, Italy, Spain and the United Kingdom reported they would consider Relvar (fluticasone furoate/vilanterol inhalation powder, GlaxoSmithKline/Theravance) as a first-line maintenance therapy for patients with treatment-naive persistent asthma, according to a press release from Decision Resources Group. The findings were based on a European physician and payer forum report.

Full Story »

Personalize your page!

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!

  • Meeting News Coverage
  • AAAAI 2014
  • Read all our coverage from the American Academy of Allergy, Asthma and Immunology annual meeting in San Diego.
More »
More »
  • Protecting patient data
  • Larry Thompson 3_11_14
  • Expert advice
  • Too many health care professionals believe too many cybersecurity myths, consultant Larry Thompson told allergists at AAAAI.
More »
  • SLIT agents are trending
  • Sublingual immunotherapy
  • presents the latest in sublingual immunotherapy FDA and research news.
More »